Skip to content

Immunome IMNM Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-5,947.9%-3,954pp-3,228.8%+154pp-2,419.9%+714pp-1,784.1%-1,994.3%
Net margin-5,593.8%-3,719pp-3,060%+180pp-2,301.3%+713pp-1,687.1%-1,875.2%
Returns
Return on equity-50.1%+19.1pp-52.1%+143pp-93%+183pp-81.2%+118pp-69.2%+85.8pp
Efficiency
Asset turnover0.0×0.0×0.0×
Liquidity
Current ratio21.7×+11.2×14.7×+10.6×8.9×+2.7×12.1×+5.0×10.5×+0.3×
Leverage
Debt-to-equity0.0×0.0×0.0×
Per Share
Book value per share$5.20+34.5%$7.26+135%$3.00-15.9%$3.09-26.9%$3.87-30.2%
Valuation
Market capitalization$2.47B+323%$2.37B+258%$1.02B+16.1%$776.15M+7.0%$585.18M-60.0%
Price / sales616.2×+563×341.4×+268×105.3×+18.6×61.7×53.5×
Price / book4.2×+2.3×3.7×+0.1×3.9×-0.2×2.9×0.0×1.9×-3.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Immunome's ratios come from?
Every ratio is computed from Immunome's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.